0001104659-22-085738.txt : 20220804
0001104659-22-085738.hdr.sgml : 20220804
20220803183051
ACCESSION NUMBER: 0001104659-22-085738
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20220804
DATE AS OF CHANGE: 20220803
EFFECTIVENESS DATE: 20220804
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Synthetic Biologics, Inc.
CENTRAL INDEX KEY: 0000894158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133808303
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-454779
FILM NUMBER: 221134078
BUSINESS ADDRESS:
STREET 1: 9605 MEDICAL CENTER DRIVE
STREET 2: SUITE 270
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: (734) 332-7800
MAIL ADDRESS:
STREET 1: 9605 MEDICAL CENTER DRIVE
STREET 2: SUITE 270
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20081027
FORMER COMPANY:
FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20061214
FORMER COMPANY:
FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19970730
D
1
primary_doc.xml
X0708
D
LIVE
0000894158
Synthetic Biologics, Inc.
9605 MEDICAL CENTER DRIVE
SUITE 270
ROCKVILLE
MD
MARYLAND
20850
(301) 417-4364
NEVADA
Adeona Pharmaceuticals, Inc.
ADEONA PHARMACEUTICALS, INC.
PIPEX PHARMACEUTICALS, INC.
SHEFFIELD PHARMACEUTICALS INC
Corporation
true
Steven
A.
Shallcross
9605 Medical Center Drive
Suite 270
Rockville
MD
MARYLAND
20850
Executive Officer
Director
Jeffrey
J.
Kraws
9605 Medical Center Drive
Suite 270
Rockville
MD
MARYLAND
20850
Director
John
Monahan
9605 Medical Center Drive
Suite 270
Rockville
MD
MARYLAND
20850
Director
Jeffrey
Wolf
9605 Medical Center Drive
Suite 270
Rockville
MD
MARYLAND
20850
Director
Biotechnology
Decline to Disclose
- 06b
false
2022-07-29
false
true
true
false
3000000
A.G.P./Alliance Global Partners
8361
None
None
590 MADISON AVENUE
36TH FLOOR
NEW YORK
NY
NEW YORK
10022
NY
NEW YORK
false
3000000
3000000
0
false
1
0
175000
true
AGP is receiving $175,000 plus out of pocket expenses
0
While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.
false
Synthetic Biologics, Inc.
/s/ Steven A. Shallcross
Steven A. Shallcross
Chief Executive Officer and Chief Financial Officer
2022-08-03